Thursday, 12 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 12 March 2026
News

Pharma ups its game in hot market

Posted 11 March 2026 PM

argenx has stepped up its game in the generalised myasthenia gravis (gMG) market, with a self-injectable version of Vyvgart.

The pre-filled syringe for self-injection, was approved last month as a 20-to-30-second subcutaneous injection ahead of the PBAC’s meeting this week at which it will be considered for PBS listing as a continuing treatment of adults with gMG who are anti-acetylcholine receptor antibody positive.

To see the whole article, please login

Popular

11 new drugs hit the TGA's desk
Who's been gifted a long weekend?
New jobs: Who's gone where?
Report exposes nuclear meds crisis
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (11)

Clinical & Medical, R&D (3)

Regulatory, Pharmacovigilance & QA (7)

Devices (1)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home